trending Market Intelligence /marketintelligence/en/news-insights/trending/6EC7lIIzu4F1H4B9PndRzw2 content esgSubNav
In This List

European Patent Office upholds BioTime patents

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


European Patent Office upholds BioTime patents

The European Patent Office upheld BioTime Inc.'s key patents to develop a treatment for retinal degenerative diseases.

"The EPO's decision to uphold these patents protecting OpRegen reinforces BioTime's ability to defend its intellectual property and patent portfolios, which is one of the largest in the pluripotent cell therapy industry," BioTime's general counsel Stephana Patton said in a statement.

The patents were challenged by a "large pharmaceutical company and an anonymous filer," the company said. OpRegen is undergoing a phase 1/2a dose-escalation study.